This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Max S. Heuer
New York +1 212 841 1067 Download V-card

Max Heuer advises public and private companies, boards of directors, special committees and financial advisors on strategic transactions and corporate governance matters, including mergers and acquisitions, activist investor situations, joint development, collaboration and licensing arrangements, and SEC reporting and compliance. Mr. Heuer regularly represents life sciences companies in transactional matters, and has advised clients in the technology, healthcare, consumer, financial, and energy sectors.

  • A global life sciences company in its acquisitions of early-stage life sciences companies.
  • A global life sciences company in its entry into collaboration and in-license arrangements with other life sciences companies to develop pharmaceutical and biologic products.
  • A financial communications and technology company in its acquisition of certain intellectual property assets for use in the development of blockchain technology, and its entry into a related joint development agreement.
  • A global life sciences company in its divestiture of global rights to certain pharmaceutical products via out-licensing agreements.
  • A publicly traded consumer company in connection with an assessment of the independence under stock exchange rules of certain members of its board of directors affiliated with the controlling stockholder.
  • The special committee of an affiliate of a publicly traded master limited partnership in connection with the disposition of assets of reporting limited partnerships for which it served as managing general partner.
  • A publicly traded life sciences company in connection with a change-of-control campaign by an activist investor, including the preparation and adoption of a shareholder rights plan.
  • A Fortune 100 consumer company in connection with the review of its anti-takeover defenses in response to the acquisition of a toe-hold position by an activist investor.
  • A global life sciences company in antitrust-related divestitures of securities and other biopharmaceutical assets.
  • Publicly traded companies in connection with the preparation of annual proxy statements (including responses to shareholder proposals and SEC no action requests) and current reports on Form 8-K.

Pro Bono

  • Represented a former Rikers Island inmate in 1983 action regarding the use of excessive force by Rikers guards.
  • Represented a disabled Brooklyn resident in her appeal of the Social Security Administration’s denial of disability benefits.
  • Represented NYC-area non-profit organizations in corporate governance and financial privacy matters.